RE: Results30 Nov 2020 07:04
“ Production of AbC-19™ Rapid test from the Alva site is now well underway with shipments to Abingdon already commenced
· Exciting opportunities for commercial launch of Mologic antigen test as we expect antigen testing to remain a key tool in controlling COVID-19 in 2021 and beyond
· Targeted production capacity of 500,000 lateral flow tests a week by the end of December remains on schedule”